Abstracts tagged "pain"

Abstract Number: 1918 • 2018 ACR/ARHP Annual Meeting
Defining Pain That Does Not Interfere with Activities Among Rheumatoid Arthritis (RA) Patients
Yvonne C. Lee¹, Patricia Katz^2,3, Amanda Quebe⁴, Luna Sun⁴, Himanshu Patel⁴, Carol L. Gaich⁴, Natalie Boytsov⁴ and Kaleb Michaud^5,6, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Forward/National Data Bank for Rheumatic Diseases, Wichita, KS, ³University of California San Francisco, San Francisco, CA, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: RA patients differ in the degree to which pain interferes with function. To improve function, an understanding of this diversity is needed. Our objectives…
Abstract Number: 1922 • 2018 ACR/ARHP Annual Meeting
Characterization of the Pharmacology and Pharmacokinetics of Cntx-4975, a High-Purity, Synthetic Trans-Capsaicin in Clinical Development for the Treatment of Moderate to Severe OA Knee Pain
James Campbell, Randall Stevens and Peter Hanson, Centrexion Therapeutics, Boston, MA
Background/Purpose: CNTX-4975, a highly purified, synthetic trans-capsaicin and long-acting, non-opioid analgesic in phase 3 trials for moderate to severe OA knee pain, has demonstrated safety…
Abstract Number: 2531 • 2018 ACR/ARHP Annual Meeting
Assessment of Pain Relief with Baricitinib By Treatment History in Patients with Refractory Rheumatoid Arthritis
Janet E. Pope¹, Amanda Quebe², Baojin Zhu², Luna Sun², Carol L. Gaich², Francesco de Leonardis², Anabela Cardoso² and Mark C. Genovese³, ¹St. Joseph's Health Care, Divsion of Rheumatology, London, ON, Canada, ²Eli Lilly and Company, Indianapolis, IN, ³Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Baricitinib (BARI) 2 mg and 4 mg once daily demonstrated significant clinical improvements compared to placebo in the phase 3 study of RA patients…
Abstract Number: 2563 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of a Potent and Highly Selective Oral Tyrosine Kinase 2 Inhibitor, BMS-986165, in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase II, Randomized, Placebo-Controlled Trial
Kim A Papp¹, Kenneth B. Gordon², Diamant Thaçi³, Akimichi Morita⁴, Melinda Gooderham⁵, Peter Foley^6,7,8, Ihab G. Girgis⁹, Sudeep Kundu⁹ and Subhashis Banerjee⁹, ¹Clinical Research and Probity Medical Research, Waterloo, ON, Canada, ²Medical College of Wisconsin, Milwaukee, WI, ³University of Luebeck, Luebeck, Germany, ⁴Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁵SKiN Centre for Dermatology, Queen’s University and Probity Medical Research, Peterborough, ON, Canada, ⁶The University of Melbourne, Melbourne, Australia, ⁷St Vincent’s Hospital Melbourne & Probity Medical Research, Melbourne, Australia, ⁸Skin & Cancer Foundation Inc, Melbourne, Australia, ⁹Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: BMS-986165, a potent and highly selective oral tyrosine kinase 2 inhibitor, inhibits signal transducer and activator of transcription (STAT)-dependent signalling pathways of interleukin-23 and…
Abstract Number: 2588 • 2018 ACR/ARHP Annual Meeting
Baseline Pain Severity As a Predictor of Pain Improvement Following Treatment with Tofacitinib in Psoriatic Arthritis
Alexis Ogdie¹, Kurt de Vlam², Andrew G Bushmakin³, Joseph C Cappelleri³, Philip J. Mease⁴, Roy Fleischmann⁵, Peter C. Taylor⁶, Valderilio F Azevedo⁷, Lara Fallon⁸, Anna Maniccia⁹ and John Woolcott¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²UZ Leuven, Leuven, Belgium, ³Pfizer Inc, Groton, CT, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶University of Oxford, Oxford, United Kingdom, ⁷Universidade Federal do Paraná, Curitiba, Brazil, ⁸Pfizer Canada, Montreal, QC, Canada, ⁹Pfizer Inc, New York, NY, ¹⁰Pfizer Inc, Collegeville, PA
Background/Purpose: Pain is a core domain of psoriatic arthritis (PsA), and it is recommended that all randomized controlled trials (RCTs) in patients (pts) with PsA…
Abstract Number: 2594 • 2018 ACR/ARHP Annual Meeting
Median Time to Pain Improvement in Patients with Psoriatic Arthritis Treated with Tofacitinib
Kurt de Vlam¹, Alexis Ogdie², Andrew G Bushmakin³, Joseph C Cappelleri³, Roy Fleischmann⁴, Peter C. Taylor⁵, Valderilio F Azevedo⁶, Lara Fallon⁷, Anna Maniccia⁸, John Woolcott⁹ and Philip J. Mease¹⁰, ¹UZ Leuven, Leuven, Belgium, ²University of Pennsylvania, Philadelphia, PA, ³Pfizer Inc, Groton, CT, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵University of Oxford, Oxford, United Kingdom, ⁶Universidade Federal do Paraná, Curitiba, Brazil, ⁷Pfizer Canada, Montreal, QC, Canada, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Collegeville, PA, ¹⁰Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Pain is a core domain of psoriatic arthritis (PsA).1 Rapid, sustained pain reduction is a priority for patients (pts) and physicians when choosing treatment.…
Abstract Number: 2652 • 2018 ACR/ARHP Annual Meeting
Engaging the Cholinergic Anti-Inflammatory Pathway By Stimulating the Vagus Nerve Reduces Pain and Fatigue in Patients with SLE
Cynthia Aranow¹, Martin Lesser², Meggan Mackay¹, Erik Anderson³, Theodoros P. Zanos², Timir Datta-Chaudhuri², Chad Bouton², Kevin J. Tracey⁴ and Betty Diamond¹, ¹The Feinstein Institute for Medical Research, Manhasset, NY, ²Feinstein Institute for Medical Research, Manhasset, NY, ³Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ⁴Laboratory of Biomedical Science, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Musculoskeletal (MS) pain is a common symptom of patients with Systemic Lupus Erythematosus (SLE) affecting up to 95% of patients and contributing to…
Abstract Number: 2868 • 2018 ACR/ARHP Annual Meeting
Tender Joint Count May Not Reflect Inflammatory Activity in Established Rheumatoid Arthritis Patients; Results from a Longitudinal Study of Tocilizumab
Hilde B Hammer¹, Inger Marie Jensen Hansen², Pentti Järvinen³, Marjatta Leirisalo-Repo⁴, Michael Ziegelasch⁵, Birte Agular⁶ and Lene Terslev⁷, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Svendborg Hospital, Svendborg, Denmark, ³Rheumatology, Kiljava Medical Research, Kiljavan, Finland, ⁴Rheumatology, University of Helsinki, Helsinki, Finland, ⁵Rheumatology, University Hospital, Linköping, Linköping, Sweden, ⁶Roche, Copenhagen, Denmark, ⁷Rheumatology, Rigshospitalet Glostrup, Copenhagen, Denmark
Background/Purpose: Tender joints may be caused by non-inflammatory pathologies but are still included in composite scores like CDAI. The present objective was to explore the…
Abstract Number: 405 • 2018 ACR/ARHP Annual Meeting
Feasibility of Enabling Self-Management and Coping with Arthritic Pain Using Exercise (ESCAPE-Pain) Programme for Knee Osteoarthritis in Malaysia
Muhammad Kamil Che Hasan^1,2, Emma Stanmore² and Chris Todd², ¹Kulliyyah (Faculty) of Nursing, International Islamic University Malaysia (IIUM), Kuantan Pahang, Malaysia, ²Division of Nursing, Midwifery and Social Work, The University of Manchester, Manchester, United Kingdom
Background/Purpose: In Malaysia around one in ten older people are diagnosed with osteoarthritis (OA), with the knee being one of the most commonly affected areas.…
Abstract Number: 446 • 2017 ACR/ARHP Annual Meeting
Methotrexate Use and Fatigue in Rheumatoid Arthritis Patients: Results from a National Patient Registry
Huifeng Yun¹, Shuo Yang², W. Benjamin Nowell³, Cooper Filby¹, Lang Chen¹ and Jeffrey R. Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX), a synthetic disease-modifying antirheumatic drug (DMARD), is the most commonly used medication for rheumatoid arthritis (RA). Considerable variations between patients taking MTX…
Abstract Number: 614 • 2017 ACR/ARHP Annual Meeting
Effect of Tofacitinib on Reducing Pain in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Alexis Ogdie¹, Kurt de Vlam², Iain B. McInnes³, Philip J Mease⁴, Philip Baer⁵, Tatjana Lukic⁶, Kenneth Kwok⁶, Cunshan Wang⁷, Ming-Ann Hsu⁷ and Anna Maniccia⁶, ¹Division of Rheumatology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UZ Leuven, Leuven, Belgium, ³Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Baer Weinberg MPC, Scarborough, ON, Canada, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), which has also been evaluated in other inflammatory rheumatic diseases…
Abstract Number: 860 • 2017 ACR/ARHP Annual Meeting
Effective Treatment of Persistent Arthritis Pain Requires Co-Modulation of TNF and Type I Interferon
Sarah Woller¹, Tony Yaksh² and Maripat Corr³, ¹Anesthesiology, UCSD, La Jolla, CA, ²Anesthesiology 0818, UCSD, La Jolla, CA, ³Division of Rheumatology, Allergy, and Immunology, UCSD, La Jolla, CA
Background/Purpose: Pain persisting beyond the resolution or control of clinical signs of rheumatoid arthritis (RA) decreases quality of life for millions of people. Unfortunately, this…
Abstract Number: 1261 • 2017 ACR/ARHP Annual Meeting
The Effects of Disease Burden, Helplessness, and Pain on Depressive Symptoms in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Sera Ramadan¹, Perry M. Nicassio², George Karpouzas³ and Sarah Ormseth⁴, ¹Internal Medicine, Dignity Health St. Mary Medical Center, Long Beach, CA, ²Cousins Center for PNI, UCLA, LA, CA, ³Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁴Rheumatology, Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: This research tested an integrated framework examining patient global assessment of disease activity (PtGA), maladaptive illness beliefs and pain as determinants of mood disturbance…
Abstract Number: 1345 • 2017 ACR/ARHP Annual Meeting
Tender Joints Have Low Associations with Patient’s Evaluation of Joint Pain and Ultrasound Findings Explored at Joint Level in Patients with Rheumatoid Arthritis
Hilde B Hammer¹, Joseph Sexton¹, Sella A. Provan², Brigitte Michelsen^3,4 and Tore Kvien⁵, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Hospital of Southern Norway trust, Kristiansand, Norway, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: In patients with rheumatoid arthritis (RA) the pain experience in joints with different degrees of joint inflammation is highly individual and dependent upon the…
Abstract Number: 1602 • 2017 ACR/ARHP Annual Meeting
Fatigue in Systemic Lupus: The Role of Disease Activity and Its Mediators
Desiree R Azizoddin¹, Meenakshi Jolly², Joel A. Block³ and Perry M. Nicassio⁴, ¹Department of Medicine and Behavioral Sciences, Rush University, Chicago, IL, ²Rush, Chicago, IL, ³Division of Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Cousins Center for PNI, UCLA, LA, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that leads to a variety of negative health outcomes. Though treatment continues to advance, fatigue…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].